Ironwood Pharmaceuticals Announces Receipt of Nasdaq Non-Compliance Notification Regarding Late 2024 Form 10-K Filing
https://investor.ironwoodpharma.com/press-releases/press-release-details/2025/Ironwood-Pharmaceuticals-Announces-Receipt-of-Nasdaq-Non-Compliance-Notification-Regarding-Late-2024-Form-10-K-Filing/default.aspx
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results; Achieves 2024 Financial Guidance
https://investor.ironwoodpharma.com/press-releases/press-release-details/2025/Ironwood-Pharmaceuticals-Reports-Fourth-Quarter-and-Full-Year-2024-Results-Achieves-2024-Financial-Guidance/default.aspx
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Investor Update Call
https://investor.ironwoodpharma.com/press-releases/press-release-details/2025/Ironwood-Pharmaceuticals-to-Host-Fourth-Quarter-and-Full-Year-2024-Investor-Update-Call/default.aspx
Ironwood Pharmaceuticals Initiates Apraglutide NDA Submission, Highlights Compelling New Data and Updates Corporate Structure to Position for the Future
https://investor.ironwoodpharma.com/press-releases/press-release-details/2025/Ironwood-Pharmaceuticals-Initiates-Apraglutide-NDA-Submission-Highlights-Compelling-New-Data-and-Updates-Corporate-Structure-to-Position-for-the-Future/default.aspx
Ironwood Pharmaceuticals to Participate in the Piper Sandler 36th Annual Healthcare Conference
https://investor.ironwoodpharma.com/press-releases/press-release-details/2024/Ironwood-Pharmaceuticals-to-Participate-in-the-Piper-Sandler-36th-Annual-Healthcare-Conference/default.aspx
Ironwood Pharmaceuticals to Participate in the Jefferies London Healthcare Conference
https://investor.ironwoodpharma.com/press-releases/press-release-details/2024/Ironwood-Pharmaceuticals-to-Participate-in-the-Jefferies-London-Healthcare-Conference/default.aspx
Ironwood Pharmaceuticals Reports Third Quarter 2024 Results
https://investor.ironwoodpharma.com/press-releases/press-release-details/2024/Ironwood-Pharmaceuticals-Reports-Third-Quarter-2024-Results/default.aspx
Once-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics and Disease Characteristics in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF), According to New STARS Phase III Data from Ironwood at ACG 2024
https://investor.ironwoodpharma.com/press-releases/press-release-details/2024/Once-Weekly-Apraglutide-Showed-Consistent-Treatment-Effect-Across-Baseline-Demographics-and-Disease-Characteristics-in-Adults-with-Short-Bowel-Syndrome-with-Intestinal-Failure-SBS-IF-According-to-New-STARS-Phase-III-Data-from-Ironwood-at-ACG-2024/default.aspx
Ironwood Pharmaceuticals to Host Third Quarter 2024 Investor Update Call
https://investor.ironwoodpharma.com/press-releases/press-release-details/2024/Ironwood-Pharmaceuticals-to-Host-Third-Quarter-2024-Investor-Update-Call/default.aspx
Ironwood Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference
https://investor.ironwoodpharma.com/press-releases/press-release-details/2024/Ironwood-Pharmaceuticals-to-Participate-in-the-2024-Wells-Fargo-Healthcare-Conference/default.aspx